BRAF and melanoma: The only targeted therapy combination that does not directly target angiogenesis is the combination of a BRAF inhibitor vemurafenib and a mitogen-activated extracellular kinase (MEK) inhibitor cobinetinib in combination with atezolizumab in advanced melanoma with BRAF V600 activation mutation.